Biological
PVX-410
PVX-410 is a biological therapy with 5 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
3(60%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
20%
Ph phase_1
4
80%
Phase Distribution
4
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
5
all time
Status Distribution
Active(3)
Completed(1)
Other(1)
Detailed Status
Active, not recruiting3
unknown1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 14 (80.0%)
Phase 21 (20.0%)
Trials by Status
unknown120%
completed120%
active_not_recruiting360%
Recent Activity
3 active trials
Showing 5 of 5
active_not_recruitingphase_1
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
NCT02886065
active_not_recruitingphase_1
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
NCT03362060
active_not_recruitingphase_1
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
NCT02826434
unknownphase_2
Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer
NCT04634747
completedphase_1
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
NCT01718899
Clinical Trials (5)
Showing 5 of 5 trials
NCT02886065Phase 1
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
NCT03362060Phase 1
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
NCT02826434Phase 1
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
NCT04634747Phase 2
Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer
NCT01718899Phase 1
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5